Clinical trials: Adolescent and Young Adult Cancer
Osteosarcoma
A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma
This Is a Multicenter, Randomized, Open-Label, Parallel-Group, Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide Versus Ifosfamide and Etoposide in Children, Adolescents…
- Trial name
- NCT04154189
- Testing
- Lenvatinib, Ifosfamide, Etoposide
- Where
- 84 sites in United States, Australia and 19 more
- Volunteers
- 81 people
- Sponsor
- Eisai Inc.
Infections, Papillomavirus
Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults
Human Papilloma virus (HPV) are viruses that cause a common infection of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the…
- Trial name
- NCT00120848
- Testing
- HPV 16/18 VLP AS04
- Where
- 27 sites in United States, Brazil and 1 more
- Volunteers
- 776 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Solid Tumor, Lymphoma
A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of surufatinib, thereby identifying the Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of surufatinib administered in combination with…
- Conditions
- Solid Tumor, Lymphoma, Osteosarcoma, Ewing Sarcoma
- Trial name
- NCT05093322
- Testing
- Surufatinib in combination with Gemcitabine
- Where
- 11 sites in United States
- Volunteers
- 13 people
- Sponsor
- Hutchmed
Locally Advanced Cervical Cancer
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have…
- Trial name
- eVOLVECervical (NCT06079671)
- Testing
- Volrustomig
- Where
- 205 sites in United States, Brazil and 17 more
- Volunteers
- 800 people
- Sponsor
- AstraZeneca
Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
A dose-escalation study to estimate maximum cummulative dose (MTCD) of CAT-8015 that can be safely administered to a participant.
- Trial name
- NCT00659425
- Testing
- CAT-8015 (Moxetumomab Pasudotox)
- Where
- 5 sites in United States, Canada
- Volunteers
- 57 people
- Sponsor
- MedImmune LLC
Infections, Papillomavirus
Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom
This is an observational cohort study to assess the risk of autoimmune disease(s) within 12 months of receiving the first dose of Cervarix® in the exposed cohort and over a comparable period in the unexposed cohorts.
- Trial name
- NCT01953822
- Testing
- Data collection
- Volunteers
- 1,053 people
- Sponsor
- GlaxoSmithKline
Advanced Cancer
A Phase I Trial of DM-CHOC-PEN in Adolescent and Young Adult (AYA) Subjects With Advanced Cancers
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) is a polychlorinated pyridyl cholesterol carbonate that is lipophilic, electrically neural, crosses the blood brain barrier (BBB), ability to localize in intracranial…
- Trial name
- NCT02889445
- Testing
- 4-Demethyl-4-cholesteryloxycarbonylpenclomedine
- Where
- United States
- Sponsor
- DEKK-TEC, Inc.
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
The purpose of the phase 1 portion (dose escalation) of the study was to establish an optimally safe and biologically active recommended phase 2 dose (RP2D) and/or to determine maximum tolerated dose (MTD) for gilteritinib in…
- Trial name
- NCT04240002
- Testing
- gilteritinib, fludarabine, cytarabine
- Where
- 7 sites in United States, Germany and 3 more
- Volunteers
- 9 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Osteosarcoma, Osteosarcoma in Children
Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma
The participants of this study will be children, adolescents, and young adults with residual osteosarcoma, which cannot be removed completely through surgery.
- Conditions
- Osteosarcoma, Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults
- Trial name
- CabOSTar (NCT06341712)
- Testing
- Cabozantinib, Best Supportive Care (BSC)
- Where
- 16 sites in United States, Belgium and 8 more
- Volunteers
- 10 people
- Sponsor
- Ipsen
Advanced Cancer, Brain Metastases
DM-CHOC-PEN for Brain Tumors in AYA Subjects
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) is a polychlorinated pyridyl cholesterol carbonate that is lipophilic, electrically neural, crosses the blood brain barrier (BBB), ability to localize in intracranial…
- Trial name
- NCT03668847
- Testing
- DM-CHOC-PEN
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- DEKK-TEC, Inc.
Tumors, Solid Malignant Tumors
Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
This is a phase 1/2 study evaluating safety, tolerability, and efficacy of lenvatinib as single-agent, and in combination with chemotherapy (ifosfamide and etoposide) in children and adolescents with refractory or relapsed solid…
- Conditions
- Tumors, Solid Malignant Tumors, Osteosarcoma, Differentiated Thyroid Cancer (DTC)
- Trial name
- NCT02432274
- Testing
- Lenvatinib, Ifosfamide, Etoposide
- Where
- 19 sites in United States, France and 4 more
- Volunteers
- 117 people
- Sponsor
- Eisai Limited